Podcast Interview Highlights POC Health Data Testi
Post# of 61
(Total Views: 322)
Posted On: 10/08/2021 4:48:13 PM
Podcast Interview Highlights POC Health Data Testing Using Innovative Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Platform
- Pharmacy services developer Avricore Health recently completed the initial phase of rolling out its HealthTab(TM) platform
- HealthTab(TM) partners with other health technology platforms to collect data from blood or other molecular samples to test them for illnesses ranging from COVID and flu to heart disease and diabetes
- Avricore’s platform is designed to not only provide medical condition information to patients, but to share it seamlessly with medical providers and researchers
- The company’s initial rollout took place through pharmacies in Ontario, Canada, but Avricore intends to continue expanding throughout Canada, into the United States and eventually into Europe
Health diagnostics technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has completed the initial rollout of its point of care platform for providing patients with lab-quality results regarding COVID and other illnesses, and the company was featured just recently in a Bell2Bell podcast discussing its history, its next goals and the plans it has for development farther down the road.
“I’ve always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future,” Avricore CEO Hector Bremner told Bell2Bell’s Stuart Smith (https://nnw.fm/gtqW0). “We’re really passionate about leading this charge. … We’ve now got a company that is in great shape and fully funded. And we’re growing, and we’ve got really a lot of blue sky ahead of us.”
Avricore’s flagship HealthTab(TM) platform partners currently with Abbott Rapid Diagnostics’ Afinion 2(TM) and ID Now(TM) analyzers, as well as Abaxis Global Diagnostics’ Piccolo Xpress to conduct blood or molecular testing at a neighborhood pharmacy and then shares the data from the tests not only with the patient, but also with medical professionals and researchers without compromising health privacy.
“Really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data and that can be used for study and research purposes, which is a very, very high demand out there in the sector,” Bremner said.
For the patient’s part, once the simple sample is collected testing takes about 15 minutes to deliver the results. The initial rollout has been accomplished by partnering with the Shoppers Drug Mart pharmacy network in Ontario, Canada, but the company anticipates continuing to expand through Shoppers Drug Mart’s almost 1,800 pharmacies across Canada, adding other pharmacies, and then entering the United States and the United Kingdom as well.
“The nice thing is all this technology that we use, everything that we’re doing down there (in the United States), is already approved so we are not at a sort of regulatory or approval risk at any level expanding internationally,” he said. “We’re also really excited about opportunities in the UK and EU, which, I think people just don’t understand how big a market that really is — it’s still bigger than China and it is a place where I think we can do business reliably. Between the U.S., UK and Canada, there’s about 110,000 pharmacies.”
Bremner said Avricore Health is also generating interest among Latin American and Caribbean countries for applications of its network in travel-related infectious disease diagnostics.
The company’s cloud-based technology provides a network for high-quality analysis not only for illnesses such as COVID and influenza, but heart disease and diabetes as well, facilitating data-based follow-ups with medical providers.
The global point-of-care diagnostics market was measured at nearly $34.5 billion in revenue last year by Fortune Business Insights, and it is expected to continue growing at a compound annual growth rate (“CAGR”) of 9.4 percent through 2028 (https://nnw.fm/aeutS).
For more information, visit the company’s website at www.AvricoreHealth.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Pharmacy services developer Avricore Health recently completed the initial phase of rolling out its HealthTab(TM) platform
- HealthTab(TM) partners with other health technology platforms to collect data from blood or other molecular samples to test them for illnesses ranging from COVID and flu to heart disease and diabetes
- Avricore’s platform is designed to not only provide medical condition information to patients, but to share it seamlessly with medical providers and researchers
- The company’s initial rollout took place through pharmacies in Ontario, Canada, but Avricore intends to continue expanding throughout Canada, into the United States and eventually into Europe
Health diagnostics technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has completed the initial rollout of its point of care platform for providing patients with lab-quality results regarding COVID and other illnesses, and the company was featured just recently in a Bell2Bell podcast discussing its history, its next goals and the plans it has for development farther down the road.
“I’ve always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future,” Avricore CEO Hector Bremner told Bell2Bell’s Stuart Smith (https://nnw.fm/gtqW0). “We’re really passionate about leading this charge. … We’ve now got a company that is in great shape and fully funded. And we’re growing, and we’ve got really a lot of blue sky ahead of us.”
Avricore’s flagship HealthTab(TM) platform partners currently with Abbott Rapid Diagnostics’ Afinion 2(TM) and ID Now(TM) analyzers, as well as Abaxis Global Diagnostics’ Piccolo Xpress to conduct blood or molecular testing at a neighborhood pharmacy and then shares the data from the tests not only with the patient, but also with medical professionals and researchers without compromising health privacy.
“Really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data and that can be used for study and research purposes, which is a very, very high demand out there in the sector,” Bremner said.
For the patient’s part, once the simple sample is collected testing takes about 15 minutes to deliver the results. The initial rollout has been accomplished by partnering with the Shoppers Drug Mart pharmacy network in Ontario, Canada, but the company anticipates continuing to expand through Shoppers Drug Mart’s almost 1,800 pharmacies across Canada, adding other pharmacies, and then entering the United States and the United Kingdom as well.
“The nice thing is all this technology that we use, everything that we’re doing down there (in the United States), is already approved so we are not at a sort of regulatory or approval risk at any level expanding internationally,” he said. “We’re also really excited about opportunities in the UK and EU, which, I think people just don’t understand how big a market that really is — it’s still bigger than China and it is a place where I think we can do business reliably. Between the U.S., UK and Canada, there’s about 110,000 pharmacies.”
Bremner said Avricore Health is also generating interest among Latin American and Caribbean countries for applications of its network in travel-related infectious disease diagnostics.
The company’s cloud-based technology provides a network for high-quality analysis not only for illnesses such as COVID and influenza, but heart disease and diabetes as well, facilitating data-based follow-ups with medical providers.
The global point-of-care diagnostics market was measured at nearly $34.5 billion in revenue last year by Fortune Business Insights, and it is expected to continue growing at a compound annual growth rate (“CAGR”) of 9.4 percent through 2028 (https://nnw.fm/aeutS).
For more information, visit the company’s website at www.AvricoreHealth.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)